share_log

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)

强生 | SC 13G:超过5%持股股东披露文件-Johnson & Johnson(8.8%),Johnson & Johnson Innovation-JJDC, Inc.(8.8%)
美股SEC公告 ·  07/30 21:11
Moomoo AI 已提取核心信息
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on July 30, 2024, indicating a significant ownership stake in Rallybio Corporation. The filing reveals that JJDC directly owns 3,636,363 shares of Rallybio's Class A Common Stock, which represents 8.8% of the company's class of securities as of April 10, 2024. This ownership percentage is based on the total number of shares outstanding as reported by Rallybio Corporation. Johnson & Johnson, headquartered in New Jersey, and its Delaware-based subsidiary, JJDC, have stated that the shares were not acquired for the purpose of changing or influencing the control of Rallybio Corporation.
强生公司通过其子公司强生创新-JJDC,于2024年7月30日向证券交易所提交了13G表格,表明其在Rallybio公司拥有重要股权。该文件显示,JJDC直接持有Rallybio公司的3,636,363股A类普通股,占公司证券类别的8.8%,截至2024年4月10日。这一所有权比例基于Rallybio公司报告的总股本。总部位于新泽西州的强生公司及其位于特拉华州的子公司JJDC表示,该份股份的购买并非为了改变或影响Rallybio公司的控制权。
强生公司通过其子公司强生创新-JJDC,于2024年7月30日向证券交易所提交了13G表格,表明其在Rallybio公司拥有重要股权。该文件显示,JJDC直接持有Rallybio公司的3,636,363股A类普通股,占公司证券类别的8.8%,截至2024年4月10日。这一所有权比例基于Rallybio公司报告的总股本。总部位于新泽西州的强生公司及其位于特拉华州的子公司JJDC表示,该份股份的购买并非为了改变或影响Rallybio公司的控制权。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息